News & Updates

Cognitive behavioural therapy for insomnia (CBT-I) or trazodone appear to be no better than placebo in the treatment of insomnia among patients undergoing long-term haemodialysis, reveals a study. In addition, trazodone use is associated with a higher incidence of serious adverse events (SAEs).

Use of gabapentinoid can potentially elevate the risk for severe exacerbation in patients with chronic obstructive pulmonary disease (COPD), suggests a study.

An analysis of three randomized controlled trials (RCTs) has shown the efficacy and safety of berdazimer gel, a topical, antiviral, nitric oxide-releasing medication, in the treatment of molluscum contagiosum (MC) lesions in patients aged 6 months and older. Application-site pain and erythema are the most common adverse events (AEs) related to treatment.

Bedtime dosing of antihypertensive medication is neither better nor worse than morning dosing when it comes to the subsequent risk of all-cause or cardiovascular mortality, according to a study.

Capivasertib, when added to fulvestrant, prolonged progression-free survival (PFS) by 4.1 months in an analysis of Chinese patients with hormone receptor–positive (HR+), HER2-negative (HER2– ABC) advanced breast cancer (ABC) whose disease had progressed on aromatase inhibitor, with or without a cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor in the phase III CAPItello-291 trial.

Patients with liver disease develop antibodies and T-cell responses following three shots of COVID-19 vaccines, while those who have been infected with SARS-CoV-2 develop mild symptoms only, reports a recent study.